215 related articles for article (PubMed ID: 35701983)
1. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Guo L; Wu Z
Neuropathology; 2022 Oct; 42(5):430-446. PubMed ID: 35701983
[TBL] [Abstract][Full Text] [Related]
2. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
6. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
[TBL] [Abstract][Full Text] [Related]
7. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
8. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
9. Daurisoline suppress glioma progression by inhibiting autophagy through PI3K/AKT/mTOR pathway and increases TMZ sensitivity.
Yin HT; Hui-Lu ; Yang JH; Li Q; Li M; Zhao QQ; Wen ZP
Biochem Pharmacol; 2024 May; 223():116113. PubMed ID: 38460907
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
[TBL] [Abstract][Full Text] [Related]
11. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
He Z; Cheng M; Hu J; Liu L; Liu P; Chen L; Cao D; Tang J
J Transl Med; 2022 Oct; 20(1):443. PubMed ID: 36183123
[TBL] [Abstract][Full Text] [Related]
12. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
13. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Zhang P; Chen XB; Ding BQ; Liu HL; He T
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455394
[TBL] [Abstract][Full Text] [Related]
14. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
16. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
17. FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Peng WX; Han X; Zhang CL; Ge L; Du FY; Jin J; Gong AH
Cell Biol Toxicol; 2017 Dec; 33(6):527-537. PubMed ID: 28185110
[TBL] [Abstract][Full Text] [Related]
18. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y
J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582
[TBL] [Abstract][Full Text] [Related]
19. The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Wei Y; Duan S; Gong F; Li Q
Biochem Biophys Res Commun; 2022 May; 603():153-159. PubMed ID: 35294905
[TBL] [Abstract][Full Text] [Related]
20. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Li H; Liu Q; Chen Z; Wu M; Zhang C; Su J; Li Y; Zhang C
Cell Death Dis; 2021 Mar; 12(3):252. PubMed ID: 33674567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]